1,690
Views
12
CrossRef citations to date
0
Altmetric
Research Articles

Human serum albumin-based nanoparticles alter raloxifene administration and improve bioavailability

, , , , &
Pages 2685-2693 | Received 24 Jun 2022, Accepted 01 Aug 2022, Published online: 16 Aug 2022

References

  • Ahmed OA, Badr-Eldin SM. (2018). In situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: formulation, characterization, and in vivo performance. Int J Nanomed 13:6325–35.
  • Ayub N, Faraj M, Ghatan S, et al. (2021). The treatment gap in osteoporosis. J Clin Med 10:3002.
  • Boura C, Menu P, Payan E, et al. (2003). Endothelial cells grown on thin polyelectrolyte mutlilayered films: an evaluation of a new versatile surface modification. Biomaterials 24:3521–30.
  • Chauhan DS, Reddy BPK, Mishra SK, et al. (2019). Comprehensive evaluation of degradable and cost-effective plasmonic nanoshells for localized photothermolysis of cancer cells. Langmuir 35:7805–15.
  • Collison CJ, Rothberg LJ, Treemaneekarn V, Li Y. (2001). Conformational effects on the photophysics of conjugated polymers: a two species model for MEH-PPV spectroscopy and dynamics. Macromolecules 34:2346–52.
  • Cooper C, Reginster JY, Cortet B, et al. (2012). Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Curr Med Res Opin 28:475–91.
  • Delmas PD, Ensrud KE, Adachi JD, et al. (2002). Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609–17.
  • Eskandarynasab M, Etemad-Moghadam S, Alaeddini M, et al. (2020). Novel osteoprotective nanocochleate formulation: a dual combination therapy-codelivery system against glucocorticoid induced osteoporosis. Nanomedicine 29:102273.
  • Fuenzalida JP, Flores ME, Móniz I, et al. (2014). Immobilization of hydrophilic low molecular-weight molecules in nanoparticles of chitosan/poly(sodium 4-styrenesulfonate) assisted by aromatic-aromatic interactions. J Phys Chem B 118:9782–91.
  • Gradauer K, Dünnhaupt S, Vonach C, et al. (2013). Thiomer-coated liposomes harbor permeation enhancing and efflux pump inhibitory properties. J Control Release 165:207–15.
  • Heringa M. (2003). Review on raloxifene: profile of a selective estrogen receptor modulator. Int J Clin Pharmacol Ther 41:331–45.
  • Hochner-Celnikier D. (1999). Pharmacokinetics of raloxifene and its clinical application. Eur J Obstet Gyneco Reprod Biol 85:23–9.
  • Hu S, Lee E, Wang C, et al. (2015). Amphiphilic drugs as surfactants to fabricate excipient-free stable nanodispersions of hydrophobic drugs for cancer chemotherapy. J Control Release 220:175–9.
  • Huang Y, Shaw MA, Mullins ES, et al. (2014). Synthesis and anticoagulant activity of polyureas containing sulfated carbohydrates. Biomacromolecules 15:4455–66.
  • Jagadish B, Yelchuri R, K B, et al. (2010). Enhanced dissolution and bioavailability of raloxifene hydrochloride by co-grinding with different superdisintegrants. Chem Pharm Bull (Tokyo) 58:293–300.
  • Kouchakzadeh H, Safavi MS, Shojaosadati SA. (2015). Efficient delivery of therapeutic agents by using targeted albumin nanoparticles. Adv Protein Chem Struct Biol 98:21–143.
  • Lee S, Lee C, Park S, et al. (2018). Facile fabrication of highly photothermal-effective albumin-assisted gold nanoclusters for treating breast cancer. Int J Pharm 553:363–74.
  • Li R, Wang H, Wang W, Ye Y. (2013). Gamma-ray co-irradiation induced graft polymerization of NVP and SSS onto polypropylene non-woven fabric and its blood compatibility. Radiat Phys Chem 91:132–7.
  • Lu R, Li WW, Katzir A, et al. (2015). Probing the secondary structure of bovine serum albumin during heat-induced denaturation using mid-infrared fiberoptic sensors. Analyst 140:765–70.
  • Mathrusri-Annapurn M, Bhanoji-Rao ME, Ravi-Kumar BVV. (2007). Spectrophotometric determination of raloxifene hydrochloride in pharmaceutical formulations. E-J Chem 4:79–82.
  • Modi A, Sen S, Adachi JD, et al. (2016). Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study. Osteoporos Int 27:1227–38.
  • Murthy A, Ravi PR, Kathuria H, Malekar S. (2020). Oral bioavailability enhancement of raloxifene with nanostructured lipid carriers. Nanomaterials (Basel) 10:1085.
  • Murthy A, Ravi PR, Kathuria H, Vats R. (2020). Self-assembled lecithin-chitosan nanoparticles improve the oral bioavailability and alter the pharmacokinetics of raloxifene. Int J Pharm 588:119731.
  • Muzio LL, Santarelli A, Orsini G, et al. (2013). MG63 and MC3T3-E1 osteoblastic cell lines response to raloxifene. Eur J Inflamm 11:797–804.
  • Orive G, Hernández RM, Rodríguez Gascó A, et al. (2003). Drug delivery in biotechnology: present and future. Curr Opin Biotechnol 14:659–64.
  • Pabbathi A, Patra S, Samanta A. (2013). Structural transformation of bovine serum albumin induced by dimethyl sulfoxide and probed by fluorescence correlation spectroscopy and additional methods. Chemphyschem 14:2441–9.
  • Peng CL, Shieh MJ, Tsai MH, et al. (2008). Self-assembled star-shaped chlorin-core poly(epsilon-caprolactone)-poly(ethylene glycol) diblock copolymer micelles for dual chemo-photodynamic therapies. Biomaterials 29:3599–608.
  • Peters T.Jr.(1958). Serum albumin. Adv Protein Chem 37:161–245.
  • Riggs BL. (2000). The mechanisms of estrogen regulation of bone resorption. J Clin Invest 106:1203–4.
  • Riggs BL, Hartmann LC. (2003). Selective estrogen-receptor modulators – mechanisms of action and application to clinical practice. N Engl J Med 348:618–29.
  • Saini D, Fazil M, Ali MM, et al. (2015). Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis. Drug Deliv 22:823–36.
  • Sinha VK, De Buck SS, Fenu LA, et al. (2008). Predicting oral clearance in humans: how close can we get with allometry? Clin Pharmacokinet 47:35–45.
  • Tabatabaei-Malazy O, Salari P, Khashayar P, Larijani B. (2017). New horizons in treatment of osteoporosis. DARU J Pharm Sci 25:2.
  • Taranta A, Brama M, Teti A, et al. (2002). The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 30:368–76.
  • Tirkey B, Bhushan B, Uday Kumar S, Gopinath P. (2017). Prodrug encapsulated albumin nanoparticles as an alternative approach to manifest anti-proliferative effects of suicide gene therapy. Mater Sci Eng C Mater Biol Appl 73:507–15.
  • Traiphol R, Charoenthai N. (2008). Effects of conformational change and segmental aggregation on photoemission of illuminophores in conjugated polymer MEH-PPV: blue shift versus red shift. Synth Met 158:135–42.
  • Tsai MH, Peng CL, Yang SJ, Shieh MJ. (2017). Photothermal, targeting, theranostic near-infrared nanoagent with SN38 against colorectal cancer for chemothermal therapy. Mol Pharm 14:2766–80.
  • Waters EA, McNeel TS, Stevens WM, Freedman AN. (2012). Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat 134:875–80.
  • Yang SJ, Huang CH, Yang JC, et al. (2020). Residence time-extended nanoparticles by magnetic field improve the eradication efficiency of Helicobacter pylori. ACS Appl Mater Interfaces 12:54316–27.
  • Yang SJ, Tseng SY, Wang CH, et al. (2020). Magnetic nanomedicine for CD133-expressing cancer therapy using locoregional hyperthermia combined with chemotherapy. Nanomedicine (Lond) 15:2543–61.
  • Yang S-J, Huang C-H, Wang C-H, et al. (2020). The synergistic effect of hyperthermia and chemotherapy in magnetite nanomedicine-based lung cancer treatment. Int J Nanomed 15:10331–47.